Literature DB >> 8210296

The risks of symptomatic vaginal candidiasis after oral antibiotic therapy.

T M MacDonald1, P H Beardon, M M McGilchrist, I D Duncan, A D McKendrick, D G McDevitt.   

Abstract

It is generally accepted that antibiotic use can result in vaginal fungal overgrowth, although evidence estimating the extent to which this causes symptomatic vaginitis is scant. In a study using the prescription of vaginal antifungal preparations as a surrogate measure of vaginal candidiasis, a cohort of women taking antibiotics had a higher incidence of vaginal candidiasis after antibiotic exposure than beforehand (relative risk 2.3; 95% confidence interval 1.9-3.0); this risk was highest in those aged 36-40 years (RR 6.0, 95% CI 2.9-12.5). The attributable risk was highest among those who were taking cephalosporins (AR 12.8%, 95% CI 9.1-16.5). In a case-control study, comparing previous antibiotic exposure among women using vaginal antifungal agents and matched controls, antibiotic exposure was higher among those using vaginal antifungal agents during the previous 28 days, with an odds ratio of 5.5 (95% CI 3.8-7.9).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8210296

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  12 in total

Review 1.  Record-linkage for pharmacovigilance in Scotland.

Authors:  J M Evans; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 2.  Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.

Authors:  Asmita Shukla; J D Sobel
Journal:  Curr Infect Dis Rep       Date:  2019-11-09       Impact factor: 3.725

3.  DNABII proteins play a central role in UPEC biofilm structure.

Authors:  Aishwarya Devaraj; Sheryl S Justice; Lauren O Bakaletz; Steven D Goodman
Journal:  Mol Microbiol       Date:  2015-04-16       Impact factor: 3.501

Review 4.  Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication.

Authors:  Malcolm Gillies; Anggi Ranakusuma; Tammy Hoffmann; Sarah Thorning; Treasure McGuire; Paul Glasziou; Christopher Del Mar
Journal:  CMAJ       Date:  2014-11-17       Impact factor: 8.262

Review 5.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

6.  Her choice: dealing with lactobacilli, vaginitis, and antibiotics.

Authors:  Marie V Pirotta; Suzanne M Garland
Journal:  Curr Infect Dis Rep       Date:  2005-11       Impact factor: 3.725

7.  Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England.

Authors:  Lynda Wilton; Monika Kollarova; Emma Heeley; Saad Shakir
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Antibiotic-associated Vulvovaginal Candidiasis.

Authors:  Jinping Xu; Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

9.  Relationship of fungal vaginitis therapy to prior antibiotic exposure.

Authors:  Douglas D Glover; Bryan Larsen
Journal:  Infect Dis Obstet Gynecol       Date:  2003

10.  The PAV trial: does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomised controlled trial [ISRCTN24141277].

Authors:  Marie Pirotta; Jane Gunn; Patty Chondros; Sonia Grover; Susan Hurley; Suzanne Garland
Journal:  BMC Fam Pract       Date:  2004-03-28       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.